Dermapharm Holding is forecast to grow earnings and revenue by 6.9% and 3.7% per annum respectively. EPS is expected to grow by 7.5% per annum. Return on equity is forecast to be 18.1% in 3 years.
Key information
6.9%
Earnings growth rate
7.46%
EPS growth rate
Pharmaceuticals earnings growth
10.3%
Revenue growth rate
3.7%
Future return on equity
18.12%
Analyst coverage
Good
Last updated
03 Jun 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
BATS-CHIXE:DMPD - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
1,299
171
186
254
5
12/31/2027
1,254
155
177
241
6
12/31/2026
1,209
139
178
241
6
3/31/2026
1,182
144
241
285
N/A
12/31/2025
1,178
132
187
229
N/A
9/30/2025
1,174
116
164
207
N/A
6/30/2025
1,191
107
175
216
N/A
3/31/2025
1,199
104
131
173
N/A
12/31/2024
1,195
114
163
201
N/A
9/30/2024
1,174
91
157
197
N/A
6/30/2024
1,147
83
146
187
N/A
3/31/2024
1,129
57
137
179
N/A
12/31/2023
1,151
62
178
219
N/A
9/30/2023
1,172
95
240
279
N/A
6/30/2023
1,151
123
267
304
N/A
3/31/2023
1,128
146
287
323
N/A
12/31/2022
1,041
134
250
289
N/A
9/30/2022
1,024
176
222
269
N/A
6/30/2022
1,004
185
191
249
N/A
3/31/2022
980
211
190
252
N/A
12/31/2021
960
210
189
250
N/A
9/30/2021
902
162
153
209
N/A
6/30/2021
858
123
115
164
N/A
3/31/2021
828
95
96
139
N/A
12/31/2020
808
86
90
131
N/A
9/30/2020
775
80
60
104
N/A
6/30/2020
760
77
58
97
N/A
3/31/2020
743
85
69
114
N/A
12/31/2019
714
77
N/A
101
N/A
9/30/2019
674
73
N/A
90
N/A
6/30/2019
639
77
N/A
109
N/A
3/31/2019
611
73
N/A
115
N/A
12/31/2018
584
75
N/A
159
N/A
9/30/2018
558
75
N/A
165
N/A
6/30/2018
525
76
N/A
137
N/A
3/31/2018
498
79
N/A
120
N/A
12/31/2017
480
78
N/A
87
N/A
9/30/2017
486
84
N/A
84
N/A
12/31/2016
455
77
N/A
77
N/A
12/31/2015
396
13
N/A
40
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMPD's forecast earnings growth (6.9% per year) is above the savings rate (3.4%).
Earnings vs Market: DMPD's earnings (6.9% per year) are forecast to grow slower than the UK market (11.4% per year).
High Growth Earnings: DMPD's earnings are forecast to grow, but not significantly.
Revenue vs Market: DMPD's revenue (3.7% per year) is forecast to grow slower than the UK market (4.6% per year).
High Growth Revenue: DMPD's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DMPD's Return on Equity is forecast to be low in 3 years time (18.1%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/21 11:36
End of Day Share Price
2026/04/23 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dermapharm Holding SE is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.